Scientists propose CDK2 enzyme as new target for cancer therapy

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted treatments known as CDK4/6 inhibitors. A new study led by Agnieszka Witkiewicz, MD, and Erik Knudsen, Ph.D., of Roswell Park Comprehensive Cancer Center and colleagues highlights the therapeutic impact of CDK2 inhibitors and is published in the journal Nature Communications.

Program designed by and for Aboriginal women sees 30% diabetes remission in participants

An innovative study, co-designed by Aboriginal Women, has led to remission of type 2 diabetes. The research described and measured how using Shared Medical Appointments, continuous glucose monitors and a sustainable, culturally relevant food program can develop self-management knowledge, skills and motivation to drastically improve glycemic control in First Nation women.